Literature DB >> 9447442

Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and APO E4 medial temporal lobe dementias. The Oxford Project to Investigate Memory and Aging.

K A Jobst1, L P Barnetson, B J Shepstone.   

Abstract

In a prospective study of more than 200 cases of dementia and 119 controls, annual technetium-99m-hexamethyl-propylene amineoxime (99mTc-HMPAO) single-photon emission computed tomography (SPECT) and annual medial temporal lobe (MTL) oriented X-ray computed tomography (CT) have been used to evaluate the diagnostic potential of functional and structural neuroimaging in the differential diagnosis of dementia. Some subjects have had up to 7 annual evaluations. So far, of 151 who have died, 143 (95%) have come to necropsy. Histology is known for 118, of whom 80 had Alzheimer's disease (AD), 24 had other "non-AD" dementias, and 14 controls with no cognitive deficit in life also had no significant central nervous system pathology. To compare the findings in the dementias with the profile of structural and functional imaging in the cognitively normal elderly, scan data from 105 living, elderly controls without cognitive deficit have also been included in the analysis. All clinical diagnoses were according to National Institute of Neurological and Communicable Disease and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) and the Diagnostic and Statistical Manual of Mental Disorders (3rd ed., rev.; DSM-III-R) criteria, and all histopathological diagnoses according to the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) criteria. Early data from this cohort have suggested that the combination of both MTL atrophy seen on CT with parietotemporal hypoperfusion on SPECT may predict the pathology of AD. The diagnostic sensitivity, specificity, accuracy, and positive and negative predictive values of the NINCDS-ADRDA and DSM-III-R criteria could be assessed in this cohort against the gold standard of histopathology. The diagnostic potential of CT evidence of MTL atrophy alone, SPECT evidence of parietotemporal hypoperfusion alone, and the combination of both of these scan changes in the same individual could then be compared against the diagnostic accuracy of clinical operational criteria in the pathologically confirmed cases. Furthermore, all of these modalities could be compared with the diagnostic accuracy of apolipoprotein E4 (Apo E4) genotyping to predict AD in the histopathologically confirmed cohort. In this population, NINCDS "probable-AD" was 100% specific, 49% sensitive, and 66% accurate; "possible-AD" was only 61% specific, but 93% sensitive and 77% accurate; and the combination of both "probable-AD" and "possible-AD" was 61% specific, 96% sensitive, and 85% accurate. DSM-III-R criteria were 51% sensitive, 97% specific, and 66% accurate. In the same cases and including the 105 living, elderly controls, the diagnostic accuracy of the Oxford Project to Investigate Memory and Aging (OPTIMA) scanning criteria showed CT alone to be 85% sensitive, 78% specific, and 80% accurate; SPECT alone had 89% sensitivity, 80% specificity, and 83% accuracy; and the combination of the two was 80% sensitive, 93% specific, and 88% accurate. The Apo E4 genotype was 74% sensitive but yielded 40% false positives in the histologically confirmed series. The diagnostic accuracy afforded by this method of CT and SPECT used alone is better than that of any established clinical criteria and reveals that the combination of MTL atrophy and parietotemporal hypoperfusion is common in AD, much less common in other dementias, and rare in normal controls. In the NINCDS-ADRDA criteria "possible-AD" cases, the combination of CT and SPECT findings alone were better in all diagnostic indices than the presence of Apo E4 alone in predicting AD. The frequent occurrence of MTL atrophy in AD and also in other "non-AD" dementias later in the course of the disease suggests the concept of medial temporal lobe dementia. This could explain some of the overlap of clinical profiles in the dementias, particularly as the dementia progresses, making clinical differential diagnosis difficult. In this context, the use of SPECT can significantly e

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9447442

Source DB:  PubMed          Journal:  Int Psychogeriatr        ISSN: 1041-6102            Impact factor:   3.878


  13 in total

1.  Applying functional MR imaging to brain-behavioral research: can we do better than simple clinical measures?

Authors:  A E George; S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

2.  Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition.

Authors:  Kathryn P Riley; Gregory A Jicha; Daron Davis; Erin L Abner; Gregory E Cooper; Nancy Stiles; Charles D Smith; Richard J Kryscio; Peter T Nelson; Linda J Van Eldik; Frederick A Schmitt
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

3.  Antemortem Prediction of Braak Stage.

Authors:  Jesper O E Carlson; Margaret Gatz; Nancy L Pedersen; Caroline Graff; Inger Nennesmo; Anna-Karin Lindström; Lotte Gerritsen
Journal:  J Neuropathol Exp Neurol       Date:  2015-11       Impact factor: 3.685

4.  Subcortical ischemic vascular dementia: assessment with quantitative MR imaging and 1H MR spectroscopy.

Authors:  A A Capizzano; N Schuff; D L Amend; J L Tanabe; D Norman; A A Maudsley; W Jagust; H C Chui; G Fein; M R Segal; M W Weiner
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

5.  Preclinical AD Workgroup staging: pathological correlates and potential challenges.

Authors:  Gregory A Jicha; Erin L Abner; Frederick A Schmitt; Richard J Kryscio; Kathryn P Riley; Gregory E Cooper; Nancy Stiles; Marta S Mendiondo; Charles D Smith; Linda J Van Eldik; Peter T Nelson
Journal:  Neurobiol Aging       Date:  2011-04-19       Impact factor: 4.673

6.  Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals.

Authors:  Carina Sihlbom; Pia Davidsson; Magnus Sjögren; Lars-Olof Wahlund; Carol L Nilsson
Journal:  Neurochem Res       Date:  2008-02-21       Impact factor: 3.996

Review 7.  Glycoproteomics in neurodegenerative diseases.

Authors:  Hyejin Hwang; Jianpeng Zhang; Kathryn A Chung; James B Leverenz; Cyrus P Zabetian; Elaine R Peskind; Joseph Jankovic; Zhen Su; Aneeka M Hancock; Catherine Pan; Thomas J Montine; Sheng Pan; John Nutt; Roger Albin; Marla Gearing; Richard P Beyer; Min Shi; Jing Zhang
Journal:  Mass Spectrom Rev       Date:  2010 Jan-Feb       Impact factor: 10.946

8.  Adipose and leptomeningeal arteriole endothelial dysfunction induced by β-amyloid peptide: a practical human model to study Alzheimer's disease vasculopathy.

Authors:  Seth Truran; Daniel A Franco; Alex E Roher; Thomas G Beach; Camelia Burciu; Geidy Serrano; Chera L Maarouf; Sara Schwab; Jenna Anderson; Joseph Georges; Peter Reaven; Raymond Q Migrino
Journal:  J Neurosci Methods       Date:  2014-07-05       Impact factor: 2.390

Review 9.  Conceptual evolution in Alzheimer's disease: implications for understanding the clinical phenotype of progressive neurodegenerative disease.

Authors:  Gregory A Jicha; Sarah A Carr
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

10.  Non-linear relationships of cerebrospinal fluid biomarker levels with cognitive function: an observational study.

Authors:  Jonathan H Williams; Gordon K Wilcock; Jeffrey Seeburger; Aimee Dallob; Omar Laterza; William Potter; A David Smith
Journal:  Alzheimers Res Ther       Date:  2011-02-17       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.